Ligand Pharmaceuticals, Inc. (LGND)
285.58
+5.40
(+1.93%)
USD |
NASDAQ |
Aug 25, 10:30
Ligand Pharmaceuticals Shareholders Equity (Quarterly) : 967.52M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 967.52M |
| March 31, 2026 | 997.32M |
| December 31, 2025 | 1.017B |
| September 30, 2025 | 950.17M |
| June 30, 2025 | 828.53M |
| March 31, 2025 | 795.53M |
| December 31, 2024 | 830.44M |
| September 30, 2024 | 841.18M |
| June 30, 2024 | 775.20M |
| March 31, 2024 | 806.52M |
| December 31, 2023 | 700.91M |
| September 30, 2023 | 667.90M |
| June 30, 2023 | 664.89M |
| March 31, 2023 | 646.32M |
| December 31, 2022 | 597.48M |
| September 30, 2022 | 816.30M |
| June 30, 2022 | 802.36M |
| March 31, 2022 | 793.19M |
| December 31, 2021 | 821.16M |
| September 30, 2021 | 812.07M |
| June 30, 2021 | 786.52M |
| March 31, 2021 | 745.84M |
| December 31, 2020 | 709.52M |
| September 30, 2020 | 697.82M |
| June 30, 2020 | 695.00M |
| Date | Value |
|---|---|
| March 31, 2020 | 661.90M |
| December 31, 2019 | 767.23M |
| September 30, 2019 | 850.58M |
| June 30, 2019 | 1.041B |
| March 31, 2019 | 1.080B |
| December 31, 2018 | 560.91M |
| September 30, 2018 | 699.52M |
| June 30, 2018 | 619.81M |
| March 31, 2018 | 481.10M |
| December 31, 2017 | 399.79M |
| September 30, 2017 | 403.17M |
| June 30, 2017 | 385.12M |
| March 31, 2017 | 371.83M |
| December 31, 2016 | 341.29M |
| September 30, 2016 | 338.26M |
| June 30, 2016 | 329.76M |
| March 31, 2016 | 364.60M |
| December 31, 2015 | 237.28M |
| September 30, 2015 | 292.18M |
| June 30, 2015 | 69.05M |
| March 31, 2015 | 35.15M |
| December 31, 2014 | 26.32M |
| September 30, 2014 | 44.37M |
| June 30, 2014 | 64.17M |
| March 31, 2014 | 65.00M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Johnson & Johnson | 84.97B |
| Eli Lilly & Co. | 33.88B |
| Merck & Co., Inc. | 41.93B |
| Zevra Therapeutics, Inc. | 217.65M |
| Liquidia Corp. | 195.11M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.186B |
| Total Liabilities (Quarterly) | 1.218B |
| Debt to Equity Ratio | 1.169 |
| Current Ratio | 31.18 |
| Net Debt Paydown Yield | -3.58% |